Adductor canal block with or without added magnesium sulfate following total knee arthroplasty: a multi-arm randomized controlled trial

• Published in: Canadian journal of anesthesia 2021-07, Vol.68 (7), p.1028-1037
• Main Authors: Zoratto, Dana, Phelan, Rachel, Hopman, Wilma M., Wood, Gavin C. A., Shyam, Vidur, DuMerton, Deborah, Shelley, Jessica, McQuaide, Sheila, Kanee, Lauren, Ho, Anthony M.-H., McMullen, Michael, Armstrong, Mitch, Mizubuti, Glenio B.
• Format: Article
• Language: English
• Subjects: Analgesics; Anesthesia; Anesthesiology; Animal behavior; Cardiology; Critical Care Medicine; Intensive; Joint replacement surgery; Joint surgery; Length of stay; Medicine; Medicine & Public Health; Morphine; Pain; Pain Medicine; Pediatrics; Pneumology/Respiratory System; Reports of Original Investigations
• ISSN: 0832-610X; 1496-8975
• DOI: 10.1007/s12630-021-01985-5

Purpose Postoperative analgesia following total knee arthroplasty (TKA) often includes intrathecal opioids, periarticular injection (PAI) of local anesthetic, systemic multimodal analgesia, and/or peripheral nerve blockade. The adductor canal block (ACB) provides analgesia without muscle weakness and magnesium sulphate (MgSO 4 ) may extend its duration. The purpose of this trial was to compare the duration and quality of early post-TKA analgesia in patients receiving postoperative ACB (± MgSO 4 ) in addition to standard care. Methods Elective TKA patients were randomized to: 1) sham ACB, 2) ropivacaine ACB, or 3) ropivacaine ACB with added MgSO 4 . All received spinal anesthesia with intrathecal morphine, intraoperative PAI, and multimodal systemic analgesia. Patients and assessors remained blinded to allocation. Anesthesiologists knew whether patients had received sham or ACB but were blinded to MgSO 4. The primary outcome was time to first analgesic (via patient-controlled analgesia [PCA] with iv morphine) following ACB. Secondary outcomes were morphine consumption, side effects, visual analogue scale pain scores, satisfaction until 24 hr postoperatively, and length of stay. Results Of 130 patients, 121 were included. Nine were excluded post randomization: four were protocol violations, three did not meet inclusion criteria, and two had severe pain requiring open label blockade. There were no differences in the median [interquartile range] time to first PCA request: sham, 310 min [165–550]; ropivacaine ACB, 298 min [120–776]; and ropivacaine ACB with MgSO 4 , 270 min [113–780] ( P  = 0.96). Similarly, we detected no differences in resting pain, opioid consumption, length of stay, or associated side effects until 24 hr postoperatively. Conclusion We found no analgesic benefit of a postoperative ACB, with or without added MgSO 4 , in TKA patients undergoing spinal anesthesia and receiving intrathecal morphine, an intraoperative PAI, and multimodal systemic analgesia. Trial registration www.clinicaltrials.gov (NCT02581683); registered 21 October 2015.